PL3578266T3 - Formulacja octanu abirateronu - Google Patents

Formulacja octanu abirateronu

Info

Publication number
PL3578266T3
PL3578266T3 PL19173089.4T PL19173089T PL3578266T3 PL 3578266 T3 PL3578266 T3 PL 3578266T3 PL 19173089 T PL19173089 T PL 19173089T PL 3578266 T3 PL3578266 T3 PL 3578266T3
Authority
PL
Poland
Prior art keywords
acetate formulation
abirateron
abirateron acetate
formulation
acetate
Prior art date
Application number
PL19173089.4T
Other languages
English (en)
Inventor
William H. Bosch
Marck Norret
Paul NEMETH
Matt Callahan
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of PL3578266T3 publication Critical patent/PL3578266T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B02CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02CCRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C19/00Other disintegrating devices or methods
    • B02C19/16Mills provided with vibrators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19173089.4T 2013-03-15 2014-03-17 Formulacja octanu abirateronu PL3578266T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789141P 2013-03-15 2013-03-15
US201361883941P 2013-09-27 2013-09-27

Publications (1)

Publication Number Publication Date
PL3578266T3 true PL3578266T3 (pl) 2024-10-21

Family

ID=51538105

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19173089.4T PL3578266T3 (pl) 2013-03-15 2014-03-17 Formulacja octanu abirateronu
PL14765788T PL2969227T3 (pl) 2013-03-15 2014-03-17 Formulacja octanu abirateronu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14765788T PL2969227T3 (pl) 2013-03-15 2014-03-17 Formulacja octanu abirateronu

Country Status (20)

Country Link
US (3) US20140287039A1 (pl)
EP (2) EP2969227B1 (pl)
JP (4) JP2016514707A (pl)
KR (3) KR102121404B1 (pl)
CN (2) CN110604721B (pl)
AU (2) AU2014232508C1 (pl)
BR (1) BR112015023629A8 (pl)
CA (1) CA2907415C (pl)
CL (1) CL2015002787A1 (pl)
ES (2) ES2741800T3 (pl)
HK (1) HK1219457A1 (pl)
IL (1) IL241612B (pl)
MX (1) MX2015013247A (pl)
NZ (1) NZ712350A (pl)
PL (2) PL3578266T3 (pl)
RU (1) RU2732136C2 (pl)
SG (2) SG11201507681PA (pl)
TW (2) TWI731321B (pl)
WO (1) WO2014145813A1 (pl)
ZA (1) ZA201507209B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9632195B2 (en) 2011-10-28 2017-04-25 Gx Technology Canada Ltd. Steerable fairing string
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
WO2015086596A1 (en) * 2013-12-12 2015-06-18 Basf Se Solid form of abiraterone acetate
WO2015114314A1 (en) * 2014-01-28 2015-08-06 Cipla Limited Pharmaceutical composition comprising abiraterone
SG11201701139YA (en) * 2014-09-18 2017-03-30 Iceutica Inc Abiraterone acetate formulation and methods of use
CN105616364B (zh) * 2014-11-07 2018-11-02 深圳万乐药业有限公司 醋酸阿比特龙片及其制备方法
SG11201704267VA (en) 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
HUE054935T2 (hu) 2014-12-05 2021-10-28 Aragon Pharmaceuticals Inc Rákellenes készítmények
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
US10722527B2 (en) * 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
WO2017136617A1 (en) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
CN109154676B (zh) 2016-02-16 2020-07-10 Gx技术加拿大有限公司 带状翼型沉降器
CA3024872A1 (en) * 2016-06-03 2017-12-07 Aragon Pharmaceuticals, Inc. Anticancer compositions
US11311493B2 (en) * 2017-04-07 2022-04-26 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
WO2019060525A1 (en) * 2017-09-22 2019-03-28 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF
US20210008081A1 (en) * 2018-03-29 2021-01-14 Leiutis Pharmaceuticals Pvt, Ltd Oral liquid formulations of abiraterone
EP3826770B1 (en) * 2018-07-24 2024-08-28 Camx Power, L.L.C. Dry milling additive and process
WO2020028558A1 (en) 2018-07-31 2020-02-06 Microbion Corporation Bismuth-thiol compositions and methods of use
HU231297B1 (hu) * 2018-07-31 2022-09-28 Richter Gedeon Nyrt Stabil gyógyszerkészítmények és eljárás az előállításukra
AU2019312592B2 (en) 2018-07-31 2025-06-26 Microbion Corporation Bismuth-thiol compositions and methods for treating wounds
CN113382922B (zh) 2018-10-09 2024-07-19 Gx技术加拿大有限公司 用于拖曳式海洋阵列的模块化翼型系统
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
AU2020240017A1 (en) * 2019-03-18 2021-11-04 AustinPx, LLC Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
KR20220087482A (ko) * 2019-10-22 2022-06-24 아비나스 오퍼레이션스, 인코포레이티드 전립선암 치료 방법
CN113133983B (zh) * 2020-01-20 2023-12-12 鲁南制药集团股份有限公司 一种治疗前列腺癌的药物组合物
CN115427016A (zh) * 2020-04-16 2022-12-02 塔凡塔医疗匈牙利公司 用于治疗前列腺癌的方法和组合物
US12103056B2 (en) 2020-05-07 2024-10-01 Nanchang University Organic waste collection apparatus and method
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CN112933053B (zh) * 2021-01-29 2022-11-25 中国药科大学 一种醋酸阿比特龙的纳米晶体及其制剂和制备方法
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
US11801252B2 (en) * 2021-03-05 2023-10-31 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition
JP7320903B2 (ja) 2021-12-15 2023-08-04 湖南慧▲澤▼生物医▲薬▼科技有限公司 アビラテロン酢酸エステルを含む組成物及び使用
KR20240010280A (ko) 2022-07-15 2024-01-23 한미약품 주식회사 아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 약제학적 조성물
WO2025163665A1 (en) * 2024-01-29 2025-08-07 Dr. Reddy’S Laboratories Limited Stable pharmaceutical compositions of abiraterone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
NZ705763A (en) * 2006-06-30 2016-10-28 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
PL2478907T3 (pl) * 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
JP2010536798A (ja) * 2007-08-17 2010-12-02 テバ ファーマシューティカル インダストリーズ リミティド 難溶性薬物の生体利用率を制御するための方法及び組成物
KR101580656B1 (ko) * 2009-04-24 2015-12-30 아이슈티카 피티와이 리미티드 디클로페낙의 신규 제형
US20120160944A1 (en) * 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
CN102438594A (zh) * 2009-04-24 2012-05-02 伊休蒂卡有限公司 吲哚美辛的新剂型
SG10201607849TA (en) * 2009-04-24 2016-11-29 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
HRP20201241T1 (hr) * 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
CN103813794A (zh) * 2011-07-18 2014-05-21 拓凯制药公司 用于治疗前列腺癌的新型组合物及方法
GB201207886D0 (en) 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
CN102743393A (zh) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
WO2014083512A1 (en) * 2012-11-28 2014-06-05 Dr. Reddy's Laboratories Limited Process for preparation of abiraterone acetate

Also Published As

Publication number Publication date
IL241612B (en) 2020-03-31
ZA201507209B (en) 2016-12-21
RU2015144285A (ru) 2017-04-24
AU2014232508A1 (en) 2015-10-08
RU2732136C2 (ru) 2020-09-11
CA2907415A1 (en) 2014-09-18
HK1220162A1 (en) 2017-04-28
AU2018241103A1 (en) 2018-10-25
CN110604721B (zh) 2022-02-08
JP7320485B2 (ja) 2023-08-03
TWI731321B (zh) 2021-06-21
US20160067265A1 (en) 2016-03-10
KR20180021932A (ko) 2018-03-05
AU2014232508B2 (en) 2018-07-12
JP2016514707A (ja) 2016-05-23
CN105246598B (zh) 2019-09-13
AU2014232508C1 (en) 2023-01-19
HK1219457A1 (zh) 2017-04-07
KR102121404B1 (ko) 2020-06-11
CN105246598A (zh) 2016-01-13
EP3578266B1 (en) 2024-06-19
SG11201507681PA (en) 2015-10-29
KR20160023641A (ko) 2016-03-03
BR112015023629A8 (pt) 2023-04-11
NZ712350A (en) 2020-08-28
KR20190141270A (ko) 2019-12-23
JP2021008521A (ja) 2021-01-28
EP3578266A1 (en) 2019-12-11
MX2015013247A (es) 2016-11-25
US20170354665A1 (en) 2017-12-14
ES2741800T3 (es) 2020-02-12
CA2907415C (en) 2022-04-05
TW201943408A (zh) 2019-11-16
TW201513896A (zh) 2015-04-16
EP2969227B1 (en) 2019-05-08
WO2014145813A1 (en) 2014-09-18
AU2018241103B2 (en) 2020-08-13
JP7752150B2 (ja) 2025-10-09
CL2015002787A1 (es) 2016-05-13
US20140287039A1 (en) 2014-09-25
SG10201709400VA (en) 2018-01-30
JP2018135351A (ja) 2018-08-30
EP2969227A4 (en) 2016-12-07
EP2969227A1 (en) 2016-01-20
BR112015023629A2 (pt) 2017-07-18
JP2023103410A (ja) 2023-07-26
ES2986853T3 (es) 2024-11-13
TWI686212B (zh) 2020-03-01
PL2969227T3 (pl) 2019-12-31
CN110604721A (zh) 2019-12-24

Similar Documents

Publication Publication Date Title
FIC20240001I1 (fi) Tislelitsumabi
FIC20240023I1 (fi) Vadadustaatti
PL3578266T3 (pl) Formulacja octanu abirateronu
EP3065716C0 (en) FORMULATIONS
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
PL2945641T3 (pl) Cykloalkinowe pochodne sacharydów
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
NL301170I2 (nl) Somatrogon
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
HUE050917T2 (hu) Hidrokortizon-tartalmú készítmény
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile
ES1078715Y (es) Mosquitera